Advanced searches left 3/3

Post-Traumatic Stress Disorder - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 12 June 2022

* If you want to update the article please login/register

Breathing Meditation Intervention for Post-Traumatic Stress Disorder

"Post traumatic stress disorder is a condition that arises as a result of exposure to a traumatic event and is characterized by intense physical and psychological vulnerability to stimuli associated with the condition. " Breathing meditation techniques, first, breathing meditation techniques provide a simple yet effective means of balancing autonomic nervous system activity that is often elevated in PTSD. It is likely that the disturbed sleep that is typical of PTSD leads to memory loss. The aim of this study is to investigate the effects of SKY meditation therapy on veterans with clinically relevant PTSD symptoms. Compared to cognitive processing therapy, which is commonly used to treat Veterans of PTSD. Following treatment with SKY, the investigators predict that the PTSD symptoms will be reduced substantially than CPT-C and that the dropout rates will be no higher than CPT-C and that the dropout rates would be no higher than CPT-C. Based on preliminary findings using SKY's PTSD and the current literature, the investigators predict that PTSD symptom severity will be reduced following treatment with SKY. Following recovery from therapy, the investigators also expect that changes in clinical measures of PTSD would correlate with increases in memory consolidation, reflecting improvements in sleep following rehabilitation. The SKY and CBT-C interventions focus on specific aspects of PTSD; the SKY and CBT-C interventions focus on breathing and relaxation techniques, while CPT-C focuses on improving trauma analysis by cognitive restructuring. However, the CPT-C intervention may be more beneficial for veterans with more cognitive disorders because CPT-C treats cognitive processes, rather than CPT-C approaches cognitive processes.

Source link: https://clinicaltrials.gov/ct2/show/NCT02366403


Post-traumatic Stress Disorder Treatment Using Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy : a Two-arm Randomized Controlled Multicentric Study - T-TREAt

"Post-Traumatic Stress Disorder is a anxiety disorder that can arise after exposure to a frightening event or ordeal in which there is the possibility or real occurrence of severe physical harm. " People with PTSD have persistent nightmares and memories of their ordeal, suffer from sleep deficiency, feel sad or numb, or be immediately startedled. "The anxiety related to the traumatic event can decrease" according to the latest PTSD treatment, which usually includes antidepressants as serotonin-specific reuptake inhibitors and Cognitive Behavioral Therapies, such as exposure therapy to trauma-linked elements. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT02900053


Optimizing Attention Bias Modification for Posttraumatic Stress Disorder: An Entirely Remote Study

"The investigators will complete a completely remote controlled trial comparing 14 sessions of attention bias reduction, attention control education, placebo control education, and a final control condition with daily questions in 1,897 people with clinically relevant Post-traumatic Stress Symptoms. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT04888169


Cannabidiol as a Treatment for Alcohol Use Disorder Comorbid With Posttraumatic Stress Disorder

"Project aims to verify the belief that CBD will reduce alcohol consumption in people with AUD comorbid with PTSD. " AUD, one of the most common and most debilitating psychiatric disorders, is often associated with other comorbid psychiatric disorders, particularly PTSD: 30-60 percent of veterans of military veterans have PTSD, with high comorbidity rates in military veterans. Evidence from animal models and clinical studies shows that the negative emotion caused by alcohol withdrawal fuels craving for alcohol during alcohol withdrawal, perpetuating the vicious cycle; more, evidence shows that the brain circuits that support negative emotion and addiction are linked in a forebrain area called the extended amygdala, which provides a neuropharmacological target to simultaneously address both negative emotion and alcohol use in individuals with AUD and PTSD. "In animal studies, CBD also reduced addictive alcohol intake. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT03248167


Enhancing Memory and Learning in Cognitive Processing Therapy for Post Traumatic Stress Disorder (PTSD)

"The success of psychological therapies for posttraumatic stress disorder is obviously limited by the difficulty participants have in learning and recalling essential therapy information. " A pilot controlled trial comparing CPT with Memory Assistance to CPT-alone will be conducted. The primary aim of the trial will be to see if CPT+MS will increase memory and understanding of therapy content relative to CPT-alone, as well as determining the acceptability and feasibility of integrating MS into CPT. A preliminary investigation into treatment efficiency, as shown by the number of changes in PTSD symptoms in various conditions, and target validation, as shown by associations between memory and learning of therapy content and treatment response. The trial findings will advance scientific understanding of memory and learning as a means for improving PTSD treatment outcomes.

Source link: https://clinicaltrials.gov/ct2/show/NCT05310097


Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder

"It will investigate the possibility and safety of administering brexanolone to men and women with PTSD/AUD. " Brexanolone will be administered as a continuous IV infusion for more than 20 hours to subjects meeting eligibility requirements. Personalized photos from the laboratory session will be used to support a 2 hour alcohol self-administration period. Subjects will then complete a follow-up period with alcohol use, PTSD symptoms, and side effects for the next 30 days. Following the administration of brexanolone for 30-days, treatment-emergent adverse events as a result of the administration of brexanolone for 30-days, as well as the percentage of milliliters consumed during ad-libitum drinking in the laboratory session were among the key outcome outcomes.

Source link: https://clinicaltrials.gov/ct2/show/NCT05223829


THE PRISM-PTSD PILOT TRIAL (Process-Instructed Self Neuro-Modulation ("Prism") Pilot Trial for Post-Traumatic Stress Disorder)

"Prism is a software package intended for neurofeedback education, and it can be used in combination with a standard computer and supported EEG hardware. The trial, as an Adjunct to the Standard of Care in Subjects with Post-Traumatic Stress Disorder, is a prospective, Single-Arm, Open-Label Pilot Trial to determine the safety and effectiveness of Process-Instructed Self Neuromodulation. The study population will include people with Post-Traumatic Stress Disorder from 1 year to 20 years after index trauma. The study's main aim is to determine the safety and effectiveness of fifteen EEG-NF training sessions using the Prism software in reducing PTSD-related symptoms.

Source link: https://clinicaltrials.gov/ct2/show/NCT04891614


Pilot Study to Assess the Feasibility of Prazosin for Cannabis Use Disorder in Individuals With or Without Post-traumatic Stress Disorder

"This pilot study seeks to determine whether prazosin is a treatment for CUD in people with or without comorbid PTSD, and to see if further study on a larger scale is warranted. " The investigators will investigate how to recruit and keep people with CUD, analyze their ability to measure cannabis use and related clinical findings, and objectively measure cannabis use in the context of a clinical trial. Although the investigators have extensive experience recruiting Veterans and non-Veterans with and without PTSD for prazosin clinical trials of similar length, they have never recruited treatment-seeking CUD participants. Specifically, Aim 1: Determine the possibility of recruiting and retaining participants in a clinical trial using prazosin as a CUD treatment. The investigators will select 20 CUD residents for a 12-week open-label treatment of prazosin. Given their experience with recruiting research in Veterans and non-Veterans with and without PTSD and/or alcohol use disorder, which resulted in 61-83% retention at the end of therapy, the investigators predict that prazosin would be well tolerated in the study population. The investigators will determine whether prazosin administration is well tolerated and is associated with a decrease in cannabis withdrawal symptoms and/or cannabis use, according to Exploratory Aims. The comparison of cannabis use throughout the study between those with and without PTSD, as well as the reduction of PTSD-related nightmares in the PTSD group are two other exploratory findings.

Source link: https://clinicaltrials.gov/ct2/show/NCT04721353


A Multi-Site Open-Label Safety Extension Study of Manualized MDMA-Assisted Psychotherapy for the Treatment of Participants With Posttraumatic Stress Disorder

"People with PTSD can be helped by psychotherapies and pharmacotherapies. " 3-Methamine is a drug that increases the neurohormones oxytocin, nopinephrine, and dopamine in the brain, and indirectly raises the levels of the neurohormones oxytocin, arginine vasopressin, and cortisol in the brain, and in the last decade, there has been a growing amount of study into medications and other ways that may increase the effectiveness of psychotherapy for PTSD. For treating PTSD, a combination of MDMA and psychotherapy may be particularly helpful. In patients with PTSD, a multi-site, open-label safety study investigates the effectiveness and safety of MDMA-assisted psychotherapy versus psychotherapy. Participants who were randomly assigned to the placebo arm in the two parent Phase 3 trials of MDMA-assisted psychotherapy's two parent trials of MDMA-assisted psychotherapy and those who met all other entry criteria will be eligible and eligible to participate in this open-label safety extension study. In addition, participants in the parent Phase 3 trials who were impacted by COVID-19 pandemic or other unexpected circumstances and were unable to finish the research can participate in this open-label study. Participants will receive an initial dose of 80 mg of MDMA, as well as a supplemental dose of 40 or 60 mg for Experimental Sessions 2 and 3. At Visit 16, the change in PCL-5 from Visit 3 is evaluated on the Primary Outcome measure, the change in Visit 3's Visit 3 is determined.

Source link: https://clinicaltrials.gov/ct2/show/NCT04714359

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions